Maximum Dose for Mounjaro
The maximum approved dose of Mounjaro (tirzepatide) is 15 mg injected subcutaneously once weekly 1.
Dosing Algorithm
The FDA-approved dosing schedule follows a structured escalation protocol 1:
- Starting dose: 2.5 mg once weekly (for treatment initiation only, not intended for glycemic control)
- After 4 weeks: Increase to 5 mg once weekly
- Subsequent escalation: If additional glycemic control or weight loss is needed, increase in 2.5 mg increments after at least 4 weeks on the current dose
- Maximum dose: 15 mg once weekly
Evidence Supporting the Maximum Dose
The 15 mg maximum dose is supported by robust clinical trial data across multiple indications:
For Type 2 Diabetes: The SURPASS trials demonstrated that tirzepatide 15 mg achieved A1C reductions of 1.9% to 2%, with >87% of participants reaching A1C targets <7% 2.
For Obesity Management: In the SURMOUNT-1 trial, the 15 mg dose produced the most substantial weight reduction at 22.5% at 72 weeks, with nearly 40% of participants losing ≥25% of their body weight 2, 3. The SURMOUNT-2 trial showed 14.7% weight reduction in patients with type 2 diabetes at the 15 mg dose 2.
For Obstructive Sleep Apnea: The FDA approved tirzepatide in December 2024 for moderate-to-severe OSA in adults with obesity, with the 15 mg dose demonstrating efficacy 2.
Clinical Considerations
Dose Escalation is Mandatory: The gradual titration schedule is critical to minimize gastrointestinal adverse events (nausea, vomiting, diarrhea), which occur most commonly during dose escalation 2. Starting at the lowest dose and escalating monthly allows the body to acclimate to the medication.
Not All Patients Require Maximum Dose: While 15 mg is the maximum approved dose, therapeutic goals may be achieved at lower doses (5 mg or 10 mg). The decision to escalate should be based on inadequate glycemic control or insufficient weight loss response after at least 4 weeks on the current dose 1.
Dose Flexibility: The approved maintenance doses are 5 mg, 10 mg, and 15 mg once weekly 2, 1. Patients should be maintained on the lowest effective dose that achieves their therapeutic goals.
Common Pitfalls to Avoid
- Rapid escalation: Accelerating the titration schedule increases gastrointestinal side effects and treatment discontinuation
- Restarting after interruption: If treatment is paused for >4 days, patients must restart at the 2.5 mg dose and re-titrate to avoid adverse events 2
- Exceeding maximum dose: There is no approved dose above 15 mg weekly; higher doses have not been studied and should not be used
The 15 mg maximum dose represents the highest FDA-approved and clinically studied dose, providing optimal efficacy for both glycemic control and weight management while maintaining an acceptable safety profile when proper titration is followed.